Limited factor VIIa surface localization requirement of the factor VIIa-induced overall thrombin generation in platelet-rich hemophilia A plasma.
factor VIIa
gamma‐carboxyglutamic acid domain
platelets
thrombelastography
thrombin peak
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
27
03
2019
revised:
27
04
2019
accepted:
27
05
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
19
10
2019
Statut:
epublish
Résumé
Thrombin generation assay (TGA) and thrombelastography (TEG) are increasingly employed, global, in vitro methods for assessment of the procoagulant potential of plasma/blood and possibly ideally suited tools to monitor, for example, therapy with recombinant factor VIIa (FVIIa). It remains controversial to what extent results obtained with spiked and postinfusion samples reflect the outcome in patients. To characterize the TGA response to FVIIa in hemophilic plasma and compare with TEG data. Hemophilia A (HA) was induced in platelet-rich plasma (PRP) from healthy volunteers, followed by spiking with FVIIa, γ-carboxyglutamic acid (Gla)-domainless FVIIa or V158D/E296V/M298Q-FVIIa (FVIIa Addition of 25 nmol L The good general responses to clinically effective concentrations of FVIIa (25 and 75 nmol L
Sections du résumé
BACKGROUND
BACKGROUND
Thrombin generation assay (TGA) and thrombelastography (TEG) are increasingly employed, global, in vitro methods for assessment of the procoagulant potential of plasma/blood and possibly ideally suited tools to monitor, for example, therapy with recombinant factor VIIa (FVIIa). It remains controversial to what extent results obtained with spiked and postinfusion samples reflect the outcome in patients.
OBJECTIVE
OBJECTIVE
To characterize the TGA response to FVIIa in hemophilic plasma and compare with TEG data.
METHODS
METHODS
Hemophilia A (HA) was induced in platelet-rich plasma (PRP) from healthy volunteers, followed by spiking with FVIIa, γ-carboxyglutamic acid (Gla)-domainless FVIIa or V158D/E296V/M298Q-FVIIa (FVIIa
RESULTS
RESULTS
Addition of 25 nmol L
CONCLUSIONS
CONCLUSIONS
The good general responses to clinically effective concentrations of FVIIa (25 and 75 nmol L
Identifiants
pubmed: 31624791
doi: 10.1002/rth2.12236
pii: S2475-0379(22)01788-5
pmc: PMC6781916
doi:
Types de publication
Journal Article
Langues
eng
Pagination
713-717Informations de copyright
© 2019 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis.
Déclaration de conflit d'intérêts
The authors are employees of Novo Nordisk A/S, the manufacturer of NovoSeven® (recombinant FVIIa).
Références
FEBS Lett. 1992 Jul 20;306(2-3):157-60
pubmed: 1633870
Haemophilia. 2015 Mar;21(2):275-283
pubmed: 25521720
Res Pract Thromb Haemost. 2019 Jun 28;3(4):713-717
pubmed: 31624791
Blood. 2014 Mar 13;123(11):1764-6
pubmed: 24425804
J Thromb Haemost. 2005 Apr;3(4):742-51
pubmed: 15842358
Biochemistry. 1988 Oct 4;27(20):7785-93
pubmed: 3264725
Blood. 2002 Feb 1;99(3):923-30
pubmed: 11806995
Blood. 2010 Dec 16;116(25):5734-7
pubmed: 20810929
Blood. 2013 Mar 14;121(11):1944-50
pubmed: 23319573
Thromb Res. 2010 Aug;126(2):144-9
pubmed: 20542542
J Thromb Haemost. 2015 Nov;13(11):2041-52
pubmed: 26340413
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13583-8
pubmed: 11698657
J Thromb Haemost. 2007 Sep;5(9):1817-24
pubmed: 17723119
Blood. 2014 Nov 13;124(20):3172-4
pubmed: 25232061
Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):389-94
pubmed: 22395575
J Thromb Haemost. 2018 Sep;16(9):1817-1829
pubmed: 29879294
Blood. 2002 Jul 1;100(1):148-52
pubmed: 12070020
J Biol Chem. 2006 Sep 29;281(39):28850-7
pubmed: 16867987
Thromb Haemost. 2001 Jun;85(6):958-65
pubmed: 11434702
J Biol Chem. 1994 Mar 18;269(11):8007-13
pubmed: 8132522
J Thromb Haemost. 2016 Mar;14(3):546-50
pubmed: 26727350
J Thromb Haemost. 2012 Aug;10(8):1478-85
pubmed: 22632160